Comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”
Comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”. // American Journal of Transplantation. – URL: https://www.sciencedirect.com/science/article/pii/S1600613526025852?dgcid=rss_sd_all
Comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”. American Journal of Transplantation. https://www.sciencedirect.com/science/article/pii/S1600613526025852?dgcid=rss_sd_all
“Comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”.” American Journal of Transplantation.
@article{article97395,
title = {Comment on “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”},
journal = {American Journal of Transplantation},
url = {https://www.sciencedirect.com/science/article/pii/S1600613526025852?dgcid=rss_sd_all}
}